Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $15.5 million.

  • Inhibrx Biosciences' Shares Outstanding (Weighted Average) rose 6.46% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 6.46%. This contributed to the annual value of $14.8 million for FY2024, which is 2562.17% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Shares Outstanding (Weighted Average) of $15.5 million as of Q3 2025, which was up 6.46% from $15.5 million recorded in Q2 2025.
  • Inhibrx Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $15.5 million during Q3 2025, with a 5-year trough of $10.9 million in Q2 2023.
  • Over the past 3 years, Inhibrx Biosciences' median Shares Outstanding (Weighted Average) value was $14.7 million (recorded in 2024), while the average stood at $13.9 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 3398.41% in 2024, then grew by 6.46% in 2025.
  • Inhibrx Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $11.8 million in 2023, then rose by 25.62% to $14.8 million in 2024, then grew by 4.57% to $15.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $15.5 million for Q3 2025, versus $15.5 million for Q2 2025 and $15.5 million for Q1 2025.